Advertisement

 

 

Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome.

Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome.
Author Information (click to view)

Berglund JA, Gafni RI, Wodajo F, Cowen EW, El-Maouche D, Chang R, Chen CC, Guthrie LC, Molinolo AA, Collins MT,


Berglund JA, Gafni RI, Wodajo F, Cowen EW, El-Maouche D, Chang R, Chen CC, Guthrie LC, Molinolo AA, Collins MT, (click to view)

Berglund JA, Gafni RI, Wodajo F, Cowen EW, El-Maouche D, Chang R, Chen CC, Guthrie LC, Molinolo AA, Collins MT,

Advertisement

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2018 01 29() doi 10.1007/s00198-017-4372-x

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic condition in which phosphaturic mesenchymal tumors (PMTs) secrete high levels of fibroblast growth factor 23 (FGF23) into the circulation. This results in renal phosphate wasting, hypophosphatemia, muscle weakness, bone pain, and pathological fractures. Recent studies suggest that fibronectin-fibroblast growth factor receptor 1 (FN1-FGFR1) translocations may be a driver of tumorigenesis. We present a patient with TIO who also exhibited clinical findings suggestive of Cowden syndrome (CS), a rare autosomal dominant disorder characterized by numerous benign hamartomas, as well as an increased risk for multiple malignancies, such as thyroid cancer. While CS is a clinical diagnosis, most, but not all, harbor a mutation in the tumor suppressor gene PTEN. Genetic testing revealed a somatic FN1-FGFR1 translocation in the FGF23-producing tumor causing TIO; however, a germline PTEN mutation was not identified. To our knowledge, this is the first reported case of concurrent TIO and CS.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × 1 =

[ HIDE/SHOW ]